Literature DB >> 6745219

Michaelis-Menten kinetics of stiripentol in normal humans.

R H Levy, P Loiseau, M Guyot, H M Blehaut, J Tor, T A Moreland.   

Abstract

Michaelis-Menten kinetic parameters for stiripentol, and anticonvulsant, were assessed in six normal volunteers. Stiripentol was administered orally three times a day in dosage increments of 600, 1,200, and 1,800 mg/day for consecutive periods of 3, 4, and 7 days, respectively. Stiripentol steady-state levels at the three dosing rates increased more than proportionally with dose. The mean +/- SD oral clearance of stiripentol at 600 mg/day (1,090 +/- 624 L/day) was significantly greater (p less than 0.01) than at 1,200 (506 +/- 219 L/day) or 1,800 (405 +/- 151 L/day) mg/day. Average steady-state concentrations predicted from individually determined Vm and Km parameters were in good agreement with experimentally observed levels, indicating that the kinetics of stiripentol are of the Michaelis-Menten type. The mean Vm, Km, and Vm/Km ratio were 2,299 +/- 490 mg/day, 2.20 +/- 1.28 mg/L, and 1,241 +/- 837 L/day, respectively. Neuropsychological tests carried out before and after 14 days of stiripentol treatment showed a significant decline in verbal learning ability (p = 0.038) and a significant improvement in a test of memory and attention (p less than 0.01).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6745219     DOI: 10.1111/j.1528-1157.1984.tb03448.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  10 in total

1.  Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis.

Authors:  Jarogniew J Luszczki; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09-14       Impact factor: 3.000

Review 2.  Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.

Authors:  Gail D Anderson; Shahin Hakimian
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

Review 3.  Stiripentol : in severe myoclonic epilepsy of infancy (dravet syndrome).

Authors:  Greg L Plosker
Journal:  CNS Drugs       Date:  2012-11       Impact factor: 5.749

Review 4.  The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine.

Authors:  E Perucca; M Bialer
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

Review 5.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

Review 6.  Comparative pharmacokinetics of the newer antiepileptic drugs.

Authors:  M Bialer
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

Review 7.  New anticonvulsant drugs. Focus on flunarizine, fosphenytoin, midazolam and stiripentol.

Authors:  M Bebin; T P Bleck
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

8.  A physiologically based pharmacokinetic model for clobazam and stiripentol in adults and children.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  Pharm Res       Date:  2014-07-23       Impact factor: 4.200

9.  Audit of use of stiripentol in adults with Dravet syndrome.

Authors:  S Balestrini; S M Sisodiya
Journal:  Acta Neurol Scand       Date:  2016-05-27       Impact factor: 3.209

10.  A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects.

Authors:  Gilmour Morrison; Julie Crockett; Graham Blakey; Kenneth Sommerville
Journal:  Clin Pharmacol Drug Dev       Date:  2019-02-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.